Eagle Pharmaceuticals Reports Positive Outcome from FDA Meeting for Ryanodex for Exertional Heat Stroke NDA Submission; Says Reduced Future Ryanodex Royalty Obligations to Licensing Partner from 15% to 3% of Net Sales for Payment of $15M in Cash